PURPOSE OF REVIEW: We will focus on the recent findings concerning the inflammatory response in vascular and renal tissues caused by hypertension. RECENT FINDINGS: Angiotensin II is one of the main factors involved in hypertension-induced tissue damage. This peptide regulates the inflammatory process. Angiotensin II activates circulating cells, and participates in their adhesion to the activated endothelium and subsequent transmigration through the synthesis of adhesion molecules, chemokines and cytokines. Among the intracellular signals involved in angiotensin II-induced inflammation, the production of reactive oxygen species and the activation of nuclear factor-kappaB are the best known. SUMMARY: The pharmacological blockade of angiotensin II actions, by angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, results in beneficial organ protective effects, in addition to the effects of these agents on blood pressure control, that can be explained by the blockade of the angiotensin II-induced pro-inflammatory response. These data provide a rationale for the use of blockers of the renin-angiotensin system to prevent vascular and renal inflammation in patients with hypertension.
PURPOSE OF REVIEW: We will focus on the recent findings concerning the inflammatory response in vascular and renal tissues caused by hypertension. RECENT FINDINGS:Angiotensin II is one of the main factors involved in hypertension-induced tissue damage. This peptide regulates the inflammatory process. Angiotensin II activates circulating cells, and participates in their adhesion to the activated endothelium and subsequent transmigration through the synthesis of adhesion molecules, chemokines and cytokines. Among the intracellular signals involved in angiotensin II-induced inflammation, the production of reactive oxygen species and the activation of nuclear factor-kappaB are the best known. SUMMARY: The pharmacological blockade of angiotensin II actions, by angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, results in beneficial organ protective effects, in addition to the effects of these agents on blood pressure control, that can be explained by the blockade of the angiotensin II-induced pro-inflammatory response. These data provide a rationale for the use of blockers of the renin-angiotensin system to prevent vascular and renal inflammation in patients with hypertension.
Authors: Raúl R Rodrigues-Diez; Ana Belen Garcia-Redondo; Macarena Orejudo; Raquel Rodrigues-Diez; Ana Maria Briones; Enrique Bosch-Panadero; Gyorgy Kery; Janos Pato; Alberto Ortiz; Mercedes Salaices; Jesus Egido; Marta Ruiz-Ortega Journal: Antioxid Redox Signal Date: 2015-01-01 Impact factor: 8.401
Authors: Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2010-04-29 Impact factor: 8.237
Authors: J Rincón; D Correia; J L Arcaya; E Finol; A Fernández; M Pérez; K Yaguas; E Talavera; M Chávez; R Summer; F Romero Journal: Life Sci Date: 2015-01-24 Impact factor: 5.037
Authors: Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz Journal: Pharmacol Rev Date: 2012-12-20 Impact factor: 25.468
Authors: Tang-Dong Liao; Xiao-Ping Yang; Yun-He Liu; Edward G Shesely; Maria A Cavasin; William A Kuziel; Patrick J Pagano; Oscar A Carretero Journal: Hypertension Date: 2008-06-09 Impact factor: 10.190